Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CELZ.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 8.655M
March 31, 2026 6.110M
December 31, 2025 7.515M
September 30, 2025 5.592M
June 30, 2025 6.828M
March 31, 2025 8.061M
December 31, 2024 6.342M
September 30, 2024 6.557M
June 30, 2024 7.613M
March 31, 2024 9.229M
December 31, 2023 10.34M
September 30, 2023 12.09M
June 30, 2023 13.73M
March 31, 2023 14.82M
December 31, 2022 15.86M
September 30, 2022 22.07M
June 30, 2022 23.04M
March 31, 2022 9.354M
December 31, 2021 10.22M
September 30, 2021 -0.3633M
June 30, 2021 -0.7145M
March 31, 2021 -2.443M
December 31, 2020 -39.80M
September 30, 2020 -2.776M
June 30, 2020 -4.205M
Date Value
March 31, 2020 -3.182M
December 31, 2019 -8.072M
September 30, 2019 -3.563M
June 30, 2019 -2.637M
March 31, 2019 -3.605M
December 31, 2018 -3.995M
September 30, 2018 -7.354M
June 30, 2018 -10.59M
March 31, 2018 -7.934M
December 31, 2017 -2.236M
September 30, 2017 -1.073M
June 30, 2017 -1.023M
March 31, 2017 -0.2997M
December 31, 2016 -0.1578M
September 30, 2016 -0.3352M
June 30, 2016 -0.2514M
March 31, 2016 -0.1889M
December 31, 2015 -0.1838M
September 30, 2015 -0.1749M
June 30, 2015 -0.1686M
March 31, 2015 -0.1623M
December 31, 2014 -0.153M
September 30, 2014 -0.1465M
June 30, 2014 -0.1408M
March 31, 2014 -0.135M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics